Neurosense Therapeutics Ltd (NRSN)

$0.83 +0.07 (9.21%)
Market Cap 27.02M
Revenue (ttm) 0.00
Net Income (ttm) -10.21M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 99,000
Avg Vol 172,448
Day's Range N/A - N/A
Shares Out 32.56M
Stochastic %K 95%
Beta 1.70
Analysts Strong Sell
Price Target $8.38

Company Profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 9 799 6183
Address:
Building B, 11 HaMenofim Street, Herzliya, Israel
Stekli27
Stekli27 Apr. 4 at 7:28 PM
$NRSN Let’s be real for a second: Yes, cash is a problem • Yes, dilution / ATM is real • And yes, without funding nothing moves forward But that’s NOT the only variable here: • This isn’t a “random biotech gamble” • PrimeC already showed meaningful signals in ALS • Multi-target approach actually makes sense for neurodegenerative diseases Now the key point everyone ignores: • Success here is NOT just about the drug • It’s about patient selection + trial design If they: • target the right population (inflammation / RNA dysregulation driven) - with help of Neurokaire • and build on prior signals Probability of success increases significantly. What matters NOW: • AD readout (coming weeks) • Financing (ATM vs partnership) • Strategy for Phase 3 ALS Most people don’t believe it right now. That’s exactly why the upside exists.
0 · Reply
Stekli27
Stekli27 Apr. 4 at 2:03 PM
$NRSN
2 · Reply
mmtiddy
mmtiddy Apr. 4 at 11:23 AM
$NRSN It needs to go higher than just $1 btw, they need $1.22 at least bc of the MVLS notification, their market cap needs to be higher than $35 million
0 · Reply
mmtiddy
mmtiddy Apr. 4 at 11:21 AM
$NRSN One thing to mention, the $1.00 rule is whatever they can reverse split cause significant damage and whatever, people will be forced to average down or sell What’s really bad is the MVLS notification, which states they need to be above $35 million market cap or they risk delisting, their market cap is only 2/3 that now, meaning if they can’t reach it before September they will dilute the stock 33% times more from their ATM offerings Good luck to the holders, but when a stock is this bad in the trenches they going to dilute and reverse split
0 · Reply
supernoob
supernoob Apr. 3 at 7:07 PM
$NRSN Alon you better hurry up! Don’t want a RS. The Silver Lining: • They have until ~October 2026 to fix it • A good news catalyst (Alzheimer's trial results) could push price above $1 • Companies survive this ALL the time What I'd Watch: • May 2026 — Health Canada NDS meeting (catalyst) • Alzheimer's trial results — "coming weeks" (could be THIS catalyst) • Any partnership news
1 · Reply
tw33ky
tw33ky Apr. 3 at 3:07 PM
$NRSN Two NASDAQ notices on minimum bid and MVLS.....reverse split then offering incoming!!!
0 · Reply
funnymoney90210
funnymoney90210 Apr. 3 at 2:04 PM
$NRSN NASDAQ notice!
1 · Reply
Babilon1210
Babilon1210 Apr. 3 at 5:51 AM
$NRSN Vol is regular so I aint puting much weight on this jump
0 · Reply
Stekli27
Stekli27 Apr. 2 at 7:59 PM
$NRSN 👀
1 · Reply
BioRich
BioRich Apr. 1 at 3:03 PM
$CYCN Congrats on the great merger news today. Long road but hopefully people still made a premium. Cheers! $VERU $LPCN $CYCN $ALUR $NRSN
0 · Reply
Latest News on NRSN
NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements

Apr 3, 2026, 10:02 AM EDT - 2 days ago

NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements

NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update

Mar 31, 2026, 9:20 AM EDT - 5 days ago

NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update

NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout

Mar 24, 2026, 9:00 AM EDT - 12 days ago

NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout

PrimeC New Data to Be Presented at AD/PD™ 2026 Conference

Mar 18, 2026, 8:00 AM EDT - 18 days ago

PrimeC New Data to Be Presented at AD/PD™ 2026 Conference

JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity

Mar 16, 2026, 11:33 AM EDT - 20 days ago

JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity

PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference

Mar 9, 2026, 11:07 AM EDT - 27 days ago

PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference

NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS

Feb 18, 2026, 9:05 AM EST - 6 weeks ago

NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS

NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition

Feb 9, 2026, 9:20 AM EST - 7 weeks ago

NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition

NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease

Jan 21, 2026, 8:30 AM EST - 2 months ago

NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease

World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB

Jan 8, 2026, 8:45 AM EST - 3 months ago

World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB

NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study

Dec 22, 2025, 9:17 AM EST - 3 months ago

NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study

NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026

Dec 4, 2025, 7:30 AM EST - 4 months ago

NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026

NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS

Nov 24, 2025, 9:56 AM EST - 4 months ago

NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS

NeuroSense to Host Investor Webinar on December 8, 2025

Nov 3, 2025, 9:15 AM EST - 5 months ago

NeuroSense to Host Investor Webinar on December 8, 2025

NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers

Oct 6, 2025, 9:00 AM EDT - 6 months ago

NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers

NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons

Sep 10, 2025, 2:30 PM EDT - 7 months ago

NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons

NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price

Sep 4, 2025, 8:49 AM EDT - 7 months ago

NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price

NeuroSense Provides Business Update and Progress for the First Half of 2025

Aug 1, 2025, 9:00 AM EDT - 8 months ago

NeuroSense Provides Business Update and Progress for the First Half of 2025

Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community

Jul 22, 2025, 8:42 AM EDT - 9 months ago

Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community

Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights

May 12, 2025, 3:08 PM EDT - 11 months ago

Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights

NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch

May 7, 2025, 8:45 AM EDT - 11 months ago

NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch

NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update

Apr 24, 2025, 9:09 AM EDT - 1 year ago

NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update

NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment

Apr 9, 2025, 8:30 AM EDT - 1 year ago

NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment

NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates

Apr 7, 2025, 5:14 PM EDT - 1 year ago

NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates

NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting

Apr 4, 2025, 9:10 AM EDT - 1 year ago

NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting

PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape

Mar 17, 2025, 8:30 AM EDT - 1 year ago

PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape

NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement

Jan 6, 2025, 9:00 AM EST - 1 year ago

NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement

NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS

Dec 23, 2024, 9:00 AM EST - 1 year ago

NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS

NeuroSense Provides Business Update and Third Quarter 2024 Financial Results

Dec 18, 2024, 10:25 AM EST - 1 year ago

NeuroSense Provides Business Update and Third Quarter 2024 Financial Results

NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC

Dec 11, 2024, 9:25 AM EST - 1 year ago

NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC

NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS

Dec 4, 2024, 8:30 AM EST - 1 year ago

NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS

NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price

Dec 2, 2024, 8:30 AM EST - 1 year ago

NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price

NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND

Nov 21, 2024, 9:20 AM EST - 1 year ago

NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND

NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission

Oct 28, 2024, 8:30 AM EDT - 1 year ago

NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission

New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients

Oct 24, 2024, 8:30 AM EDT - 1 year ago

New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients

NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates

Oct 15, 2024, 9:15 AM EDT - 1 year ago

NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates

NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada

Oct 9, 2024, 9:00 AM EDT - 1 year ago

NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada

NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting

Oct 7, 2024, 9:00 AM EDT - 1 year ago

NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting

NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's

Sep 24, 2024, 9:05 AM EDT - 1 year ago

NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's

NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule

Sep 24, 2024, 9:00 AM EDT - 1 year ago

NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule

NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification

Aug 30, 2024, 4:30 PM EDT - 1 year ago

NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification

NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price

Aug 7, 2024, 2:00 PM EDT - 1 year ago

NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price

NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial

Aug 1, 2024, 9:15 AM EDT - 1 year ago

NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial

NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression

Jul 9, 2024, 9:27 AM EDT - 1 year ago

NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression

This cheap biotech offers investors a play on ALS if trial data continues to impress

Jul 2, 2024, 12:34 PM EDT - 1 year ago

This cheap biotech offers investors a play on ALS if trial data continues to impress

NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug

Jul 1, 2024, 8:00 AM EDT - 1 year ago

NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug

NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results

Jun 24, 2024, 9:00 AM EDT - 1 year ago

NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results

NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal

Jun 21, 2024, 4:30 PM EDT - 1 year ago

NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal

NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit

May 20, 2024, 9:00 AM EDT - 2 years ago

NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit

Stekli27
Stekli27 Apr. 4 at 7:28 PM
$NRSN Let’s be real for a second: Yes, cash is a problem • Yes, dilution / ATM is real • And yes, without funding nothing moves forward But that’s NOT the only variable here: • This isn’t a “random biotech gamble” • PrimeC already showed meaningful signals in ALS • Multi-target approach actually makes sense for neurodegenerative diseases Now the key point everyone ignores: • Success here is NOT just about the drug • It’s about patient selection + trial design If they: • target the right population (inflammation / RNA dysregulation driven) - with help of Neurokaire • and build on prior signals Probability of success increases significantly. What matters NOW: • AD readout (coming weeks) • Financing (ATM vs partnership) • Strategy for Phase 3 ALS Most people don’t believe it right now. That’s exactly why the upside exists.
0 · Reply
Stekli27
Stekli27 Apr. 4 at 2:03 PM
$NRSN
2 · Reply
mmtiddy
mmtiddy Apr. 4 at 11:23 AM
$NRSN It needs to go higher than just $1 btw, they need $1.22 at least bc of the MVLS notification, their market cap needs to be higher than $35 million
0 · Reply
mmtiddy
mmtiddy Apr. 4 at 11:21 AM
$NRSN One thing to mention, the $1.00 rule is whatever they can reverse split cause significant damage and whatever, people will be forced to average down or sell What’s really bad is the MVLS notification, which states they need to be above $35 million market cap or they risk delisting, their market cap is only 2/3 that now, meaning if they can’t reach it before September they will dilute the stock 33% times more from their ATM offerings Good luck to the holders, but when a stock is this bad in the trenches they going to dilute and reverse split
0 · Reply
supernoob
supernoob Apr. 3 at 7:07 PM
$NRSN Alon you better hurry up! Don’t want a RS. The Silver Lining: • They have until ~October 2026 to fix it • A good news catalyst (Alzheimer's trial results) could push price above $1 • Companies survive this ALL the time What I'd Watch: • May 2026 — Health Canada NDS meeting (catalyst) • Alzheimer's trial results — "coming weeks" (could be THIS catalyst) • Any partnership news
1 · Reply
tw33ky
tw33ky Apr. 3 at 3:07 PM
$NRSN Two NASDAQ notices on minimum bid and MVLS.....reverse split then offering incoming!!!
0 · Reply
funnymoney90210
funnymoney90210 Apr. 3 at 2:04 PM
$NRSN NASDAQ notice!
1 · Reply
Babilon1210
Babilon1210 Apr. 3 at 5:51 AM
$NRSN Vol is regular so I aint puting much weight on this jump
0 · Reply
Stekli27
Stekli27 Apr. 2 at 7:59 PM
$NRSN 👀
1 · Reply
BioRich
BioRich Apr. 1 at 3:03 PM
$CYCN Congrats on the great merger news today. Long road but hopefully people still made a premium. Cheers! $VERU $LPCN $CYCN $ALUR $NRSN
0 · Reply
Channelchek
Channelchek Apr. 1 at 1:06 PM
Noble Capital Markets Research Report: NeuroSense Therapeutics Ltd. ($NRSN) – NeuroSense Reports FY2025 With Outlook For The Year FY2025 Reported With PrimeC Progress Review. NeuroSense reported a loss for FY2025 of $11.1 million or $(0.44) per share. The company gave updates to its ongoing PrimeC development programs and expected milestones for the coming year in ALS and Alzheimer’s disease. As of December 31, 2025, NeuroSense had cash of approximately $0.2 million. Read full report here: https://www.channelchek.com/news-channel/neurosense-therapeutics-ltd-nrsn-neurosense-reports-fy2025-with-outlook-for-the-year
0 · Reply
Babilon1210
Babilon1210 Apr. 1 at 11:07 AM
$NRSN Is this a fake jump?
1 · Reply
Babilon1210
Babilon1210 Apr. 1 at 8:37 AM
$NRSN Lets get some happy passover news
0 · Reply
Fighting_ALS
Fighting_ALS Mar. 31 at 9:21 PM
$NRSN My take-home message - "Advancing toward key regulatory milestones with planned pre-NDS meeting in Canada and near-term Alzheimer's readout"
1 · Reply
IrishSean
IrishSean Mar. 31 at 8:39 PM
$NRSN They are one failed fundraise away from shutdown imho.
1 · Reply
Stekli27
Stekli27 Mar. 31 at 6:12 PM
$NRSN Looks like the ATM is on again. Alon collecting cash… hopefully enough this time to actually start Phase 3. 🤣
0 · Reply
mmtiddy
mmtiddy Mar. 31 at 3:24 PM
$NRSN Their next earnings is very soon, I would say this week been more than 3 months, let’s see how much of that ATM they used Very telling to see how deep they are in the shits, I am expecting they must have used 1/4th by now otherwise there is no way they can initiate Phase 3 by mid 2026
0 · Reply
boilerrm04
boilerrm04 Mar. 31 at 2:44 PM
$NRSN ongoing partnership discussions…. What are the term limits? Like 400 + days 14 months and counting. Any NDAs should have been announced by now.
0 · Reply
Soul_snatcher
Soul_snatcher Mar. 31 at 1:41 PM
$NRSN as of now the company is with one leg in the grave. it ended 2025 with 200k in cash, that is ridiculous… no news about partnership or a way to fun P3. they pay their employees with more shares instead of money, which dilute us. all in this report: https://finance.yahoo.com/sectors/healthcare/articles/neurosense-therapeutics-reports-end-2025-132000198.html Alon ben noon, you should resign and let someone else save this company. until then, Fuck you and go to Hell.
0 · Reply
Soul_snatcher
Soul_snatcher Mar. 30 at 2:04 PM
$NRSN yes, it is clear that he is a joke… too bad for us and for primeC
0 · Reply
mmtiddy
mmtiddy Mar. 30 at 1:59 PM
$NRSN Reminder, this is the CEO that runs this company, how can you trust him? He has lied multiple times, it’s been 400 days since this tweet, and we have still have no proper answer on the delay of the partnership - it is completely removed from the slide deck And the capital raise questions, oh wow.
0 · Reply
mmtiddy
mmtiddy Mar. 30 at 1:51 PM
$NRSN
0 · Reply